New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:38 EDTCPXXCelator announces data, recommendation to continue CPX-351 Phase 3 study
Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:45 EDTCPXXCelator announces Phase 3 study of CPX-351 achieves target enrollment
Subscribe for More Information
October 23, 2014
07:23 EDTCPXXCelator Pharmaceuticals raises $12.9M in common stock and warrats
Subscribe for More Information
October 17, 2014
13:00 EDTCPXXCelator Pharmaceuticals files automatic common stock, warrant shelf
Celator Pharmaceuticals announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants are being offered in units consisting of one share of common stock and a warrant to purchase 0.10 of a share of common stock. Roth Capital Partners and National Securities Corporation are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use